

# **Study of the Lipophilicity and ADMET Parameters of New Anticancer Diquinothiazines with Pharmacophore Substituents**

**Daria Klimoszek <sup>1</sup>, Małgorzata Jeleń <sup>2,\*</sup>, Małgorzata Dołowy <sup>1</sup> and Beata Morak-Młodawska <sup>2</sup>**

<sup>1</sup> Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska Street 4, 41-200 Sosnowiec, Poland; d201204@365.sum.edu.pl (D.K.); mdolowy@sum.edu.pl (M.D.)

<sup>2</sup> Department of Organic Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska Street 4, 41-200 Sosnowiec, Poland; bmlodawska@sum.edu.pl

\* Correspondence: manowak@sum.edu.pl

## Content:


1. Table S1. The absorption and metabolism descriptors for compounds <b>1 – 15</b> .	2
2. Table S2. The excretion and toxicity descriptors for compounds <b>1 – 15</b> .	3
3. Figure S1. The bioavailability radars for compounds <b>1 – 15</b> .	4
4. Table S3. The summary formulas, molecular weights, melting points and appearance of the tested diquinethiazines <b>1 – 15</b> .	5

**Table S1.** The absorption and metabolism descriptors for compounds **1 – 15**.

No. of Compound	P-glycoprotein Substrate	P-glycoprotein I Inhibitor	P-glycoprotein II Inhibitor	CYP2D6 Substrate	CYP3A4 Substrate	CYP1A2 Inhibitior	CYP2C19 Inhibitior	CYP2C9 Inhibitior	CYP2D6 Inhibitior	CYP3A4 Inhibitior
<b>1</b>	-	+	+	-	+	+	-	-	+	+
<b>2</b>	+	+	+	-	+	+	+	-	+	-
<b>3</b>	+	+	+	-	+	+	-	-	-	+
<b>4</b>	+	+	+	-	+	+	-	-	-	+
<b>5</b>	+	+	+	-	+	+	+	-	+	+
<b>6</b>	+	+	+	-	+	+	-	-	+	+
<b>7</b>	+	+	+	-	+	+	-	-	+	+
<b>8</b>	+	+	+	-	+	+	+	-	+	+
<b>9</b>	+	+	+	-	+	+	+	-	+	+
<b>10</b>	+	+	+	-	+	+	-	-	+	+
<b>11</b>	+	+	+	-	+	+	+	-	+	+
<b>12</b>	+	+	+	-	+	+	-	-	+	+
<b>13</b>	+	+	+	+	+	+	-	-	+	+
<b>14</b>	+	+	+	+	+	+	-	-	+	+
<b>15</b>	+	+	+	-	+	+	+	-	+	+

**Table S2.** The excretion and toxicity descriptors for compounds **1 – 15**.

No. of Compound	Renal OCT2 Substrate	AMES Toxicity	hERG I Inhibitor	hERG II Inhibitor	Hepatotoxicity	Skin Sensitisation
<b>1</b>	-	+	-	+	+	-
<b>2</b>	-	-	-	+	+	-
<b>3</b>	-	-	-	+	+	-
<b>4</b>	-	+	-	+	+	-
<b>5</b>	-	+	-	+	+	-
<b>6</b>	-	+	-	+	+	-
<b>7</b>	-	+	-	+	+	-
<b>8</b>	+	+	-	+	+	-
<b>9</b>	+	+	-	+	+	-
<b>10</b>	-	-	-	+	+	-
<b>11</b>	-	+	-	+	+	-
<b>12</b>	-	+	-	+	+	-
<b>13</b>	-	+	-	+	+	-
<b>14</b>	-	-	-	+	+	-
<b>15</b>	-	+	-	+	+	-



**Figure S1.** The bioavailability radars for compounds **1 – 15**.

**Table S3.** The summary formulas, molecular weights, melting points and appearance of the tested diquinothiazines **1-15**.

No. of Compound	Chem. Formula	Mol. wt.	Physical Appearance	Melting Point °C (lit. m.p. [24])
<b>1</b>	C <sub>24</sub> H <sub>24</sub> N <sub>4</sub> S	400,50	yellow oil	-
<b>2</b>	C <sub>23</sub> H <sub>22</sub> N <sub>4</sub> S	386,52	yellow solid	129.8 - 130.7 (130 - 131)
<b>3</b>	C <sub>24</sub> H <sub>22</sub> N <sub>4</sub> S	398,53	yellow oil	-
<b>4</b>	C <sub>25</sub> H <sub>24</sub> N <sub>4</sub> S	412,56	orange oil	-
<b>5</b>	C <sub>26</sub> H <sub>26</sub> N <sub>4</sub> S	426,58	yellow solid	144.2 - 145.0 (144 - 145)
<b>6</b>	C <sub>24</sub> H <sub>24</sub> N <sub>4</sub> S	400,50	yellow oil	-
<b>7</b>	C <sub>23</sub> H <sub>22</sub> N <sub>4</sub> S	386,52	yellow oil	-
<b>8</b>	C <sub>24</sub> H <sub>22</sub> N <sub>4</sub> S	398,53	yellow oil	-
<b>9</b>	C <sub>25</sub> H <sub>24</sub> N <sub>4</sub> S	412,56	orange oil	-
<b>10</b>	C <sub>26</sub> H <sub>26</sub> N <sub>4</sub> S	426,58	orange oil	-
<b>11</b>	C <sub>24</sub> H <sub>24</sub> N <sub>4</sub> S	400,50	yellow oil	-
<b>12</b>	C <sub>23</sub> H <sub>22</sub> N <sub>4</sub> S	386,52	yellow oil	-
<b>13</b>	C <sub>24</sub> H <sub>22</sub> N <sub>4</sub> S	398,53	yellow oil	-
<b>14</b>	C <sub>25</sub> H <sub>24</sub> N <sub>4</sub> S	412,56	orange oil	-
<b>15</b>	C <sub>26</sub> H <sub>26</sub> N <sub>4</sub> S	426,58	orange solid	143.5 – 144.8 (144 - 145)